pharmaceutical expenditure for patients with hypertension. RESULTS: Pharmaceutical expenditures increased with age and the duration of hypertension. A mixed effect model indicated that being widowed or separated significantly increased pharmaceutical expenditures by $219.12 (P < 0.0001) and $206.84 (P < 0.0001) respectively, while the pharmaceutical expenditures decreased by $2.79 (P < 0.01) if BMI decreased by 1 kg/m² from survey round 3 to round 5. Pharmaceutical expenditures decreased with education level. Conclusively, those with public insurance spent $208.33 (P < 0.0001) more, and those with private insurance spent $121.01 (P < 0.0001) more on prescribed medicine for essential hypertension.

CONCLUSIONS: Age, duration of hypertension, marriage status, BMI, and level of education were found as significant determinants of pharmaceutical expenditures for patients with hypertension.

PCV40 EVALUATING HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH BLOOD PRESSURE CONTROL IN PATIENTS WITH NEWLY TREATED HYPERTENSION

Chang B1, Flicker W2, Shinnomoto M1, Pulcharam veetil J1, Wong K3

1HealthCare Partners Medical Group, Torrance, CA, USA; 2HealthCare Partners Medical Group, Arcadia, CA, USA; 3HealthCare Partners Medical Group, Los Angeles, CA, USA; 4NovoLine Corporation, East Hanover, NJ, USA

OBJECTIVES: To investigate the association between blood pressure (BP) control and healthcare utilization and costs in newly treated patients with hypertension in a managed care organization. METHODS: Patients who met the selection criteria were identified from a healthcare organization during July 2005 – May 2008: 1) age ≥ 18; 2) hypertension diagnosis; 3) new prescription for hypertension; 4) continuously eligible with the organization 6 months before and 12 months after the initiation of the antihypertensive agent(s) (index date); and 5) ≥2 blood pressure (BP) readings at 1 ± index date, and another measured over 90 days of recent medications. Patients were classified into BP at goal versus BP not at goal by the mean BP during 90 to 365 days after the index date. BP goal is defined as <140/90 mmHg for hypertensive patients without diabetes, and <130/80 mmHg for hypertensive patients with diabetes. Health care utilization and costs for the 12-months after index date, compared between groups. RESULTS: Wilmington. RESULTS: Those who met the index date, and another measured over 90 days of recent medications, were identified 1056 patients, the mean age was 63 years old, and 54% were females. Overall, there were 61% of patients with BP at goal and 36% of the patients with comorbid hypertension and diabetes met BP goal. The patients who met BP goal had higher number of outpatient visits (19.0 vs. 14.0; p < 0.001), higher prescription fills (31.0 vs. 25.0; p < 0.001), and higher total costs ($7016 vs. $4628; p < 0.001) than those not at goal. CONCLUSIONS: To achieve BP goal, physicians would have to follow-up with patients frequently and emphasize the benefits of maintaining BP to goal. Although the economic benefits of BP control is not immediately seen in the first year treatment, other studies have shown that long term costs do prevented the complications of hypertension, and demonstrate the long term economic benefits. Additional research is warranted.

PCV41 ANALYSIS OF DIRECT COSTS ASSOCIATED WITH INR MONITORING AND WARFARIN DOSE ADJUSTMENT IN PATIENTS WITH ATRIAL FIBRILLATION

Bolicka M1, Vassilakos EVA1, Apsitak Y2, Haytova A1

1Russian State Medical University, Moscow, Russia; 2Research Institute for Physiocochemical Medicine, Moscow, Russia; 3Moscow Center for Pharmacoeconomics, Moscow, Russia

OBJECTIVES: To analyze the structure of expenses associated with warfarin dose adjustment and consequent international normalized ratio (INR) monitoring for effective stroke prevention in patients with atrial fibrillation. METHODS: The present study demonstrates the cost of illness associated with INR monitoring and warfarin dose adjustment were calculated for four different circumstances: 1) for obligatory medical insurance system according the current general tariff agreement; 2) for patients managed in outpatient University hospital using prices for consultations and coagulation tests; 3) for those controlling INR in commercial laboratory using their price list; and 4) for self-monitored patients using costs for coagulometer and test strips purchasing. RESULTS: Within the obligatory medical insurance system total expenses for warfarin management accounted for 4058 Roubles/person per year, but share of expenses for warfarin purchasing was less than 1%, for patients treated in outpatient department of University clinic that estimated for 13019 Roubles/person per year and 0.03%, in the case of INR control in commercial laboratory – 18648 Roubles/person per year and 0.02%, and for self-monitoring – from 40,405 Roubles/person per year (0.01%) in the first year (that includes the fee for coagulometer purchasing) to 7405 Roubles/person per year (0.05%) in consequent years respectively. CONCLUSIONS: Regardless the strategy of INR control, comcomitant expenses associated with warfarin dose adjustment and subsequent efficiency and safety monitoring is more than 100-fold higher than the price of warfarin itself.

PCV42 COST ANALYSIS OF VENOUS THROMBOEMBOLISM PROPHYLAXIS AFTER TOTAL KNEE REPLACEMENT AND TOTAL HIP REPLACEMENT

Marmarali B1, Altintas F2, Bal K3, Demiri M4, Erdemli B5, Ince B3, Ongen G3, Arslan A4, Keyser BM5, Mould JP6

1IECS Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina; 2Bristol-Myers Squibb Company, Lima, Peru, 3Bristol-Myers Squibb Company, Buenos Aires, Argentina, 4Bristol-Myers Squibb Company, Mumbai, India, 5Bristol-Myers Squibb Company, Mexico, DF, Mexico, 6Bristol-Myers Squibb Company, Wallingford, CT, USA

OBJECTIVES: Orthopedic surgery presents a high risk of venous thromboembolism (VTE). Without prophylaxis, between 41% and 85% of patients who undergo high-risk orthopedic procedures develop deep vein thrombosis (DVT) and up to 10% develop pulmonary embolism (PE). Furthermore, the economic burden of VTE is dramatic, especially in Colombia. Few data on the economic burden of VTE associated with orthopedic surgery, however, is available in the country. The objective of this study was to quantify the economic burden of DVT and PE in the Colombian health care setting. METHODS: Delphi Panel methodology was used to estimate 2011 resource utilization associated with VTE treatment events in patients undergoing hip and knee replacement. Delphi Panel contained 16 specialists from the private Colombian setting. Local available databases and published literature was retrieved. Cost estimations (inpatient and outpatient costs, acquisition costs, bleedings costs, intra-cranial hemorrhages and other associated costs) considered the private perspective, using unit cost data from Seguro Obligatorio de Accidentes de Tránsito (SOAT). RESULTS: In Colombia the cost of hip replacement surgery (in 2011 USD) was estimated at USD $3182 and the cost of knee replacement at USD $2942. Mean symptomatic PE costs for inpatients with hip replacement was USD $6651 and DVT mean costs was USD $4601. Cost of treating minor bleeding adverse events was USD $1263. Cost of major bleeding adverse events was USD $4157 and major bleeding as USD $6171. The mean symptomatic PE costs (2011 USD) for inpatients with knee replacement was USD $5348 and DVT was USD $3810. Cost of treating minor bleeding adverse events in patients with knee replacement, was estimated at USD $1263. Cost of major bleeding as USD $4157. The occurrence of VTE related events to orthopedic surgery can significantly impact overall costs of orthopedic surgery in Colombia.

PCV43 ECONOMIC BURDEN OF VENOUS THROMBEMBOLISM IN ORTHOPEDIC SURGERY PATIENTS IN COLOMBIA

Caporale J1, Garrido S2, Waschbusch M3, Nunez SM4, Gutierrez-ardila MV4, Alcaraz A5, Garay OU6, Aello O7, Mould JP8, Juarez-garcia A9, Donato BMK10

1IECS Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina; 2Bristol-Myers Squibb Company, Lima, Peru, 3Bristol-Myers Squibb Company, Buenos Aires, Argentina, 4Bristol-Myers Squibb Company, Mumbai, India, 5Bristol-Myers Squibb Company, Mexico, DF, Mexico, 6Bristol-Myers Squibb Company, Wallingford, CT, USA

OBJECTIVES: Venous thromboembolism (VTE) is a significant public health issue in Colombia. The diagnosis and treatment of VTE accounts for approximately 4% of total health care expenditures in Colombia. The objective of this study is to document the health care resource utilization and costs associated with the care of VTEp and its complications related to hip and knee replacement in Argentina. METHODS: Data regarding health care resources associated with the treatment of VTE and major and minor bleeding was estimated using Delphi panel methodology in 2011 [specialists from public and private organizations, locally available databases and published literature]. The estimation of the occurrence of VTE related events to orthopedic surgery can significantly impact overall costs of orthopedic surgery in Colombia.

PCV44 FINANCIAL IMPACT OF BLEEDING EVENTS ON TOTAL KNEE AND HIP REPLACEMENTS IN THE ARGENTINE HEALTH CARE SYSTEM

Hofmann ME1, Aello O2, Garay U3, Lacerca C4, Waschbusch M5, Garrido S6, Alcaraz A7, Juarez-garcia A8, Donato BMK9, Mould JP10

1IECS Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina, 2Bristol-Myers Squibb Company, Buenos Aires, Argentina, 3Bristol-Myers Squibb Company, Lima, Peru, 4Bristol-Myers Squibb Company, Mexico, DF, Mexico, 5Bristol-Myers Squibb Company, Wallingford, CT, USA, 6IECS Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina, 7IECS Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina, 8IBS Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina, 9IECS Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina, 10IECS Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina

OBJECTIVES: Deep vein thrombosis (DVT) and pulmonary embolism (PE) are clinical manifestations of VTE that can occur with or without symptoms. A major risk factor for VTE is orthopedic surgery. The economic burden of recurrent VTE associated to hip and knee replacement is perceived as considerable high within the Argentinean health care system; however, the data supporting this perception is scarce. The objective of this study is to document the health care resource utilization and costs associated with the care of VTEp and its complications related to hip and knee replacement in Argentina. METHODS: Data regarding health care resources associated with the treatment of VTE and major and minor bleeding was estimated using Delphi panel methodology in 2011 [specialists from public and private organizations, locally available databases and published literature]. Cost of major bleeding associated with VTE was estimated as USD $4510 while the cost of DVT was estimated in USD $2904. Cost of treating minor bleeding adverse events was estimated at USD $1263. Cost of major bleeding as USD $4157. The occurrence of VTE related events to orthopedic surgery can significantly impact overall costs of orthopedic surgery in Argentina.